Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL918848 | 1.00 | AKR1C1 (0.54) | AKR1C1MAPTMEN1HTTKMT2A | |
| SCHEMBL368124 | 1.00 | AKR1C1 (0.54) | AKR1C1MAPTMEN1HTTKMT2A | |
| SCHEMBL9950184 | 0.85 | ESR1 (0.57) | MAPTMEN1HTTKMT2ANPC1 | |
| Cinnamic Acid SCHEMBL17240386 | 0.82 | HCAR2 (0.70) | AKR1C1MAPTMEN1KMT2ARAB9A | |
| SCHEMBL2495017 | 0.80 | KMO (0.52) | AKR1C1PRMT1 | |
| SCHEMBL22829697 | 0.80 | CHAT (0.55) | AKR1C1MAPTMEN1HTTKMT2A | |
| SCHEMBL14836770 | 0.79 | AKR1C1 (0.56) | AKR1C1MAPTMEN1HTTKMT2A | |
| SCHEMBL19433105 | 0.79 | PTGS1 (0.47) | MAPTMEN1HTTKMT2ANPC1 | |
| SCHEMBL9858496 | 0.79 | MAPT (0.58) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL1647472 | 0.78 | ALDH1A1 (0.44) | AKR1C1MEN1KMT2APRMT1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1845957-B1 | METHOD FOR PRODUCING A DRUG EXTRACT THAT CONTAINS HYDROXYSTILBENES | HEGER PETER (DE) | 2010-12-22 | — | — | EP | claimed |
| WO-2010049390-A1 | COSMETIC AND DERMATOLOGICAL COMPOSITIONS FOR THE REDUCTION OF FACIAL EXPRESSION WRINKLES | HENKEL AG & CO. KGAA (DE) | 2010-05-06 | — | — | WO | claimed |
| EP-1844784-B1 | A pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system | EPITECH GROUP SRL (IT) | 2010-04-21 | — | — | EP | claimed |
| EP-2005941-A2 | Cellular rejuvenation compounds | Henkel AG & Co. KGaA (DE) | 2008-12-24 | — | — | EP | claimed |
| EP-1845957-A1 | METHOD FOR PRODUCING A DRUG EXTRACT THAT CONTAINS HYDROXYSTILBENE | Heger, Peter (DE) | 2007-10-24 | — | — | EP | claimed |
| WO-2006082071-A1 | METHOD FOR PRODUCING A DRUG EXTRACT THAT CONTAINS HYDROXYSTILBENE | HEGER PETER (DE) | 2006-08-10 | — | — | WO | claimed |
| EP-2238968-B1 | Skin treatment fighting skin aging | HENKEL AG & CO KGAA (DE) | 2018-05-02 | — | — | EP | disclosed |
| EP-2238967-B1 | Skin treatment fighting skin aging II | HENKEL AG & CO KGAA (DE) | 2018-05-02 | — | — | EP | disclosed |
| EP-2202215-B1 | Novel process for the synthesis of (E)-Stilbene derivatives which makes it possible to obtain resveratrol and piceatannol | CLARIANT SPECIALTY FINE CHEM F (FR) | 2013-10-02 | — | — | EP | disclosed |
| EP-2049459-B1 | NOVEL PROCESS FOR THE SYNTHESIS OF (E)-STILBENE DERIVATIVES WHICH MAKES IT POSSIBLE TO OBTAIN RESVERATROL AND PICEATANNOL | CLARIANT SPECIALTY FINE CHEM F (FR) | 2013-10-02 | — | — | EP | disclosed |
| US-8101804-B2 | Process for the synthesis of (E)-stilbene derivatives which makes it possible to obtain resveratrol and piceatannol | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2012-01-24 | — | — | US | disclosed |
| EP-2238967-A2 | Skin treatment fighting skin aging II | Henkel AG & Co. KGaA (DE) | 2010-10-13 | — | — | EP | disclosed |
| EP-2238968-A2 | Skin treatment fighting skin aging | Henkel AG & Co. KGaA (DE) | 2010-10-13 | — | — | EP | disclosed |
| US-20080119649-A1 | HALOCOMBSTATINS AND METHODS OF SYNTHESIS THEREOF | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY | 2008-05-22 | — | — | US | disclosed |
| WO-2008012321-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF (E)-STILBENE DERIVATIVES WHICH MAKES IT POSSIBLE TO OBTAIN RESVERATROL AND PICEATANNOL | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2008-01-31 | — | — | WO | disclosed |
| US-20070167412-A1 | HALOCOMBSTATINS AND METHODS OF SYNTHESIS THEREOF | ARIZONA BOARD OF REGENTS (US) | 2007-07-19 | — | — | US | disclosed |
| EP-1802560-A2 | HALOCOMBSTATINS AND METHODS OF SYNTHESIS THEREOF | Arizona Board Regents, a body corporate of the State of Arizona, acting for and on behalf of Arizona State University (US) | 2007-07-04 | — | — | EP | disclosed |
| US-7223747-B2 | Halocombstatins and methods of synthesis thereof | ARIZONA BOARD OF REGENTS ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2007-05-29 | — | — | US | disclosed |
| WO-2006036743-A2 | HALOCOMBSTATINS AND METHODS OF SYNTHESIS THEREOF | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20050176688-A1 | Halocombstatins and methods of synthesis thereof | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119649-A1 | HALOCOMBSTATINS AND METHODS OF SYNTHESIS THEREOF | TUBB3, TUBB8B, TUBB8 | AKR1C1 3954/4885MAPT 258/4885MEN1 2337/4885 |
| US-20070167412-A1 | HALOCOMBSTATINS AND METHODS OF SYNTHESIS THEREOF | TUBB3, TUBB8B, TUBB8 | AKR1C1 3954/4885MAPT 258/4885MEN1 2337/4885 |
| US-20050176688-A1 | Halocombstatins and methods of synthesis thereof | TUBB3, TUBB8B, TUBB8 | AKR1C1 3954/4885MAPT 258/4885MEN1 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.